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Cook University, Cairns, Queensland, Australiac; Microbiology Department, Austin Pathology, Austin Health, Victoria, Australiad; and Telethon Institute for Child Health
Research, Centre for Child Health Research, University of Western Australia, Perth, Western Australiae
Streptococcus pyogenes is commonly believed to be resistant to trimethoprim-sulfamethoxazole (SXT), resulting in reservations
about using SXT for skin and soft tissue infections (SSTI) where S. pyogenes is involved. S. pyogenes’ in vitro susceptibility to
SXT depends on the medium’s thymidine content. Thymidine allows S. pyogenes to bypass the sulfur-mediated inhibition of
folate metabolism and, historically, has resulted in apparently reduced susceptibility of S. pyogenes to sulfur antibacterials. The
low thymidine concentration in Mueller-Hinton agar (MHA) is now regulated. We explored S. pyogenes susceptibility to SXT on
various media. Using two sets of 100 clinical S. pyogenes isolates, we tested for susceptibility using SXT Etests on MHA contain-
ing defibrinated horse blood and 20 mg/liter -NAD (MHF), MHA with sheep blood (MHS), MHA alone, MHA with horse blood
(MHBA), and MHA with lysed horse blood (MHLHBA). European Committee on Antibacterial Susceptibility Testing (EUCAST)
breakpoints defined susceptibility (MIC,<1 mg/liter) and resistance (MIC,>2 mg/liter). In study 1, 99% of S. pyogenes isolates
were susceptible to SXT on MHA, MHBA, and MHLHBA, with geometric mean MICs of 0.04, 0.04, and 0.05 mg/liter, respec-
tively. In study 2, all 100 S. pyogenes isolates were susceptible to SXT on MHF, MHS, MHA, and MHLHBA with geometric mean
MICs of 0.07, 0.16, 0.07, and 0.09 mg/liter, respectively. This study confirms the in vitro susceptibility of S. pyogenes to SXT, pro-
viding support for the use of SXT for SSTIs. A clinical trial using SXT for impetigo is ongoing.
Streptococcus pyogeneswas one of the first bacterial infections tobe treated with sulfur antibacterials in the 1930s (16) and
proved to be clinically effective in the treatment and prophylaxis
of S. pyogenes infections (10, 16, 23, 29). However, when sulfadi-
azine, an early short-acting sulfur antibacterial, was used in mass
prophylaxis programs to prevent S. pyogenes tonsillitis and acute
rheumatic fever (ARF) inmilitary recruits in the 1940s, the clinical
efficacy of this antibacterial was limited due to the presumed de-
velopment of resistance (13, 15, 27, 31, 42) among some strains.
Initial antibacterial susceptibility testing (AST) of S. pyogenes to
sulfur antibacterials using a broth dilution method demonstrated
that some strains were resistant (25, 53); however, AST was in its
infancy and no standardized reference methods existed at that
time. This early experience resulted in the belief that trim-
ethoprim-sulfamethoxazole (SXT) is ineffective against S. pyo-
genes, and its use has been discouraged in clinical practice for
decades (35).
Subsequent antibacterial susceptibility experiments showed
apparently reduced susceptibility of S. pyogenes (and other bacte-
ria) (6, 40) to the sulfur antibacterials due to antagonism of the
inhibition of folate metabolism. Harper and Cawston discovered
an inhibitory substance in 1945, eventually identified as thymi-
dine, which was interfering with the ability of sulfur antibacterials
to kill the organism (25). Because the activity of SXT is determined
by the antibacterial’s ability to deprive an organism of folate co-
enzymes (7), there is a direct relationship between the thymidine
levels in culture media and SXT resistance (11). High thymidine
content in agar provides an exogenous substrate which can be
used by an organism to maintain folate metabolism and hence
appear resistant to SXT. In early studies, most culture media con-
tained sufficient thymidine to antagonize the inhibitory effects of
sulfur drugs and hence produced resistant results when this class
of antibacterials was tested (6).
Notably, lysed horse blood was found to contain the enzyme
thymidine phosphorylase, which neutralized thymidine (46) and
overcame this effect (21, 25). No other mammalian blood con-
tains thymidine phosphorylase (21). However, the addition of
lysed horse blood was not recommended for AST, despite several
authors (5, 6, 21, 54) advising supplementation with lysed horse
blood for anymediumused to test sulfur antibacterial susceptibil-
ity if the thymidine concentration was above 0.03 g/ml (5) (be-
low which inhibition does not occur). In this context, the notion
that S. pyogenes was resistant to sulfur antibacterials perpetuated.
SXT was introduced in 1968 (3, 28, 43) and has since become
one of the most widely used antibacterials in the world. However,
recommendations against the use of sulfur antibacterials, includ-
ing SXT, for S. pyogenes infections continue in the belief that the
organism is intrinsically resistant (33, 47, 51). Two studies (33, 51)
have reported S. pyogenes uniformly resistant to SXT, but this was
prior to thymidine content standardization in Mueller-Hinton
agar (MHA) and was on agar containing sheep blood. There have
also been reported clinical failures in the use of this agent in erad-
icating S. pyogenes from nasopharyngeal carriage (30). However,
other centers have demonstrated full in vitro susceptibility of S.
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pyogenes to SXT (14, 22, 36, 54). Since 2006, when the thymidine
content of MHA became strictly regulated by the Clinical and
Laboratory Standards Institute (CLSI) to maintain a low level of
thymidine and hence avoid inhibition (M6-A2 protocol) (9), it
has no longer been necessary to add lysed horse blood to the me-
dium for AST. However, current methods do use agar supple-
mented with mammalian blood.
Given the prevailing view that caution should be exercised in
using SXT for infections involving S. pyogenes and the paucity of
clinical data of SXT efficacy against S. pyogenes, we sought to con-
firm or disprove the notion that S. pyogenes is resistant to SXT in
vitro on various antibacterial susceptibility testing media. Coin-
fection of S. pyogenes with Staphylococcus aureus in skin and soft
tissue infections (SSTI) and the rising prevalence of methicillin-
resistant S. aureus (MRSA) provide added stimulus to explore the
utility of SXT in the treatment of these infections.
MATERIALS AND METHODS
Swab collection and identification of S. pyogenes. Skin, throat, or nose
swabs were collected using a rayon tipped cotton swab (Copan, Interpath
Services, Melbourne, Australia). In study 1, swabs were plated on horse
blood agar (HBA) (Oxoid, Basingstoke, United Kingdom) and HBA con-
taining colistin and nalidixic acid (HBA CNA) (Oxoid) within 48 h of
collection. In study 2, swabs were stored in skim milk-tryptone-glucose-
glycerol broth (STGGB) at70°C prior to plating on the above-described
media. Incubation was at 37°C for 16 h in 5%CO2. -Hemolytic colonies
were identifiedmorphologically, and confirmation of S. pyogeneswaswith
the Lancefield streptococcal grouping test for group A (Oxoid). Isolates
were stored in glycerol at70°C until subsequent replating for AST.
Selection of isolates. (i) Study 1.Webegan by exploring the issuewith
a preliminary study of 100 skin and throat isolates of S. pyogenes collected
from 3 remote Australian Aboriginal communities between 2003 and
2005 during surveillance studies (39). We used an SXT Etest strip (bio-
Mérieux, France) on 3 different agars: MHA, MHA supplemented with
horse blood (MHBA), and MHA supplemented with lysed horse blood
(MHLHBA) (Oxoid). Interpretation was based on European Committee
on Antibacterial Susceptibility Testing (EUCAST) breakpoints (20) re-
leased in 2010.
(ii) Study 2. The Skin Sore Trial is a randomized, controlled trial
(RCT) comparing benzathine penicillin G (BPG) treatment of impetigo
(the standard of care)with oral SXT. The first 100 S. pyogenes isolates from
skin and nasal swabs from participants in the Skin Sore Trial were used in
study 2. The participants were 3 months to 13 years old and were from 4
remote Aboriginal communities of the Top End of the Northern Terri-
tory, Australia, recruited in 2010. Swabs were collected from the anterior
nares and at least 2 purulent or crusted sores from all children. Swabswere
collected from skin sores on day 0 (pretreatment), day 2 (midtreatment),
and day 7 (completion of treatment). Consent for participation and col-
lection of specimens was obtained from the guardian or parent of each
participant. The study was approved by the Northern Territory Top End
Human Research Ethics Committee (HREC 09/08) and has been regis-
tered with the Australian and New Zealand Clinical Trials Registry
(ACTRN 12609000858291).
Antibacterial susceptibility testing methods and agar used. The two
internationally accredited, standardized methods for AST (Table 1) are
the CLSI (8) and EUCAST (19)methods. CLSI does not provide reference
breakpoints for S. pyogenes susceptibility to SXT and recommends the use
of Mueller-Hinton agar (MHA) supplemented with 5% sheep blood for
testing the susceptibility of S. pyogenes to other antibacterials. In contrast,
EUCAST has released breakpoints for the disk diffusionmethod andMIC
on appropriate media. The medium recommended for Streptococcus
groups A, B, C, and G is MHA supplemented with 5% defibrinated horse
blood 20 mg/liter -NAD. This agar is commonly referred to as MHF
(http://www.eucast.org, accessed 25 July 2012).
Two experimental agars were also used for susceptibility testing.MHA
is routinely used in a number of other antibacterial susceptibility tests not
involving -hemolytic streptococci. MHLHBA was used to explore the
hypothesis based on historical literature that the lysing of horse blood
releases thymidine phosphorylase which breaks thymidine down to thy-
mine.
Using the EUCAST breakpoints (20), with an MIC of 1 mg/liter as
sensitive and an MIC of 2 mg/liter as resistant, and an SXT Etest to
perform antibacterial susceptibility, these studies compared the various
media that have been recommended for AST. The Etest interpretation is
based on the trimethoprim component of the trimethoprim-sulfame-
thoxazole combination, in a ratio of 1:19. The EUCAST methodology
using the Etestwas chosendue to the availability of published breakpoints;
however, due to the widespread use of CLSI, themedium uponwhich this
organism is tested was also used and results obtained were referenced to
the EUCAST breakpoints.
Antibacterial susceptibility testing. Single colonies were isolated
from frozen stocks following overnight incubation on HBA in 5% CO2 at
37°C. Susceptibility testing for SXT was performed using a 0.5McFarland
suspension to create a confluent lawn inoculumand then applying an SXT
Etest as per the manufacturer’s instructions. Plates were read by 2 readers
following incubation in 5% CO2 at 35°C for 16 to 20 h. The MIC was
recorded where the inhibition ellipse intersected the scale.Where a differ-
ence in results ofmore than 2 gradations was noted between the 2 readers,
a repeat test was performed with a fresh subculture of S. pyogenes. As SXT
is a bacteriostatic antibacterial, this mode of action can alter the appear-
ance of an MIC endpoint, resulting in hazy zones. Where haze was pres-
ent, both the 80% and 100% points of ellipse intersection were recorded.
A penicillin, erythromycin, and clindamycin disk diffusion test according
to CLSI guidelines (8) was conducted concurrently on all 100 strains in
study 2.
Quality control. In study 2, for every 20 S. pyogenes clinical isolates, a
control strain of S. pyogenes (ATCC 19615) was also tested on the 4 agars
and found to be susceptible. Quality control of the SXT Etests was per-
formed throughout the study using Escherichia coli (ATCC 25922) on
MHA and Streptococcus pneumoniae (ATCC 49619) on MHS. The refer-
ence ranges for each organismwere achieved, namely, 0.064 to 0.25g/ml
for E. coli and 0.125 to 1 g/ml for S. pneumoniae.
STATA version 12.0 (STATAcorp, College Station, TX) was used to
determine the geometric means. The data were logarithmically trans-
formed to a normal distribution, and paired t tests were used to determine
the difference between agars for studies 1 and 2.
TABLE 1 Antibiotic susceptibility testing methods and agar used
Method Study Agar used Abbreviation
CLSI (8) 2 Mueller-Hinton agar
supplemented
with 5% sheep
blood
MHS
EUCAST (19) 2 Mueller-Hinton agar
supplemented
with 5%
defibrinated horse
blood -NAD
MHF
Experimental 1 and 2 Mueller-Hinton agar MHA
Experimental 1 and 2 Mueller-Hinton agar
containing 5%
lysed horse blood
MHLHBA
Experimental 1 Mueller-Hinton agar
containing horse
blood
MHBA
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RESULTS
Study 1. On MHBA and MHLHBA, S. pyogenes isolates from the
skin (n  36) and throat (n  64) were uniformly susceptible to
SXT (Table 2). Ninety-nine isolates tested on MHA were suscep-
tible to SXT (Table 2). The single isolate which appeared resistant
on MHA was susceptible on both MHBA and MHLHBA.
There was no statistically significant difference between the
geometric meanMICmeasurements onMHA andMHBA. How-
ever, isolates tested on both MHA and MHBA had lower MICs
than isolates tested on MHLHBA (Table 3).
Study 2. One hundred isolates of S. pyogenes from 43 children
were included in this analysis. S. pyogenes isolates utilized were
from sores (n 98) and the anterior nares (n 2). The majority
of isolates (76%)were fromday 0 (before antibacterial treatment);
19% were from day 2, and 5% were from day 7. Sixty-four of the
swabs from which S. pyogenes was identified also cultured S. au-
reus. Of these, 14% were methicillin-resistant S. aureus (MRSA)
and 86% were methicillin-susceptible S. aureus (MSSA).
All 100 isolates of S. pyogenes were susceptible to SXT on all
agars by both readers (Table 4). Interrater reliability was excellent,
with 96%of allMIC readingswithin1MIC gradation. In viewof
this, all analyses were done on results from reader 1. All 100 S.
pyogenes isolates were also susceptible to penicillin, erythromycin,
and clindamycin.
The geometric means were similar for MHA, MHBA, and
MHLHBA (Table 4). MHS had a higher geometric mean MIC
than the other media. This was statistically significant, with iso-
lates tested onMHS having higher geometricmeanMICs than the
same isolates tested on all other agars (Table 5). Despite the higher
MICs, all isolates tested on MHS were still susceptible to SXT.
There was no difference in MIC between isolates tested on MHA
and those tested on MHF. As in study 1, isolates tested on MHA
had lower MICs than the same isolates tested on MHLHBA. This
was also found for isolates tested on MHF (Table 5).
Ongoing surveillance with in vitro susceptibility testing is
needed to monitor for changes in rates of SXT resistance with
increased use of SXT. To date, we have tested 910 S. pyogenes
isolates cultured from impetigo and anterior nares of children
randomized in the Skin Sore Trial on MHF using an SXT Etest
according to EUCAST guidelines. Only 8 (0.9%) have been found
to be resistant, with MICs of 2 mg/liter (unpublished data).
These results are consistentwith those reported from the EUCAST
group.
DISCUSSION
Although SXT is no longer commonly recommended for treat-
ment of respiratory tract infections, it remains one of the most
widely used and cheapest antibacterials in the world and is an
important option for treatment of SSTI, where S. pyogenes and S.
aureus are often copathogens (4, 12, 24, 34). In the era of rising
MRSA prevalence, antibacterials that are active against both bac-
teria are highly valued.
Impetigo is a significant therapeutic problem in remote com-
munities in the Northern Territory of Australia (37, 49, 50), with
community-associated MRSA having become highly prevalent in
this region (50). Impetigo is also an endemic problem in many
less-developed countries (41, 45), andMRSA is likely to be on the
rise in these contexts also (50). In patients with MRSA and S.
pyogenes coinfection, finding a single oral agent that is effective,
affordable, and easy to use would be a significant advance. Peni-
cillins and cephalosporins are no longer an option for MRSA
treatment. In the Northern Territory context, clindamycin is not
an option, with up to 22% of MRSA isolates resistant (49), aside
from its poor palatability in young children and the difficulties in
maintaining adherence to a thrice-daily regimen. Tetracyclines
are not recommended in children under 8 years of age (17), and
linezolid is currently too expensive for the empirical treatment of
such a common childhood condition. SXT, which is cheap,
widely available, and well tolerated and requires only twice-
daily dosing, is a potential single agent for treatment of both
MRSA and S. pyogenes infections. Several studies have con-
TABLE 2 SXT Etest susceptibility results for study 1
Medium
% of isolates
Geometric
mean MIC
(mg/liter) SD (log)
Susceptible (MIC
1 mg/liter)
Resistant (MIC
2 mg/liter)
MHBA 100 0 0.04 1.52
MHA 99 1 0.04 2.2
MHLHBA 100 0 0.05 1.78
TABLE 3 Difference in MIC in study 1a
Medium
Difference in MICb
MHA MHLHBA
MHBA MHBA lower by 7%
(9% to 20%)
MHBA lower by 25%*
(13% to 35%)
MHA MHA lower by 20%*
(3% to 33%)
a Pairwise comparisons of geometric mean MICs of various media.
b 95% confidence level in parentheses. *, P 0.05.
TABLE 4 SXT Etest susceptibility results for study 2
Medium
% of susceptible
isolates (MIC
1 mg/liter)
Geometric
mean MIC
(mg/liter) SD (log)
MHF 100 0.07 2.05
MHS 100 0.16 1.79
MHA 100 0.07 2.03
MHLHBA 100 0.09 2.3
TABLE 5 Difference in MIC in study 2a
Medium
Difference in MICb
MHF MHA MHLHBA
MHS MHS higher by
128%*
(107% to
150%)
MHS higher by
132%*
(113% to
153%)
MHS higher by
92%* (70%
to 116%)
MHF MHF higher by
2% (12%
to 7%)
MHF lower by
16%* (3% to
27%)
MHA MHA lower by
17%* (6% to
27%)
a Pairwise comparisons of geometric mean MICs of various media.
b 95% confidence level in parentheses. *, P 0.05.
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firmed the ongoing susceptibility of S. aureus to SXT in this
region of Australia (38, 49).
The breakpoints utilized for this study were defined by
EUCAST using data collated from a wide range of sources on more
than2,500 isolates of S. pyogenes tested for susceptibility to SXTusing
a variety of methods (32). Of the 2,596 tests reported frommultiple
sources, geographical areas, and time periods, 2,559 were susceptible
to SXT of1 mg/liter and 23 isolates were resistant (0.9%) (Euro-
pean Committee on Antimicrobial Susceptibility Testing, data from
theEUCASTMICdistributionwebsite, http://mic.eucast.org, last ac-
cessed 18 September 2012). On disk diffusion testing for S. pyogenes
using SXT disks in a ratio of 1:19, a zone size of18 mm indicates
susceptibility and 15 mm indicates resistance. Using these break-
points, a total of 358 testswere performed,with 5 confirmed resistant
strains (1.4%) (http://mic.eucast.org, last accessed 18 September
2012). This can be contrasted with results found in U.S.-based liter-
ature using the CLSI methods, where AST for S. pyogenes is per-
formed on agar supplemented with defibrinated sheep blood and
SXT is not routinely tested, as S. pyogenes strains are considered uni-
versally resistant (51). Defibrinated sheep blood is utilized, as the
hemolytic reactions of -hemolytic streptococci on blood agar con-
taining sheep blood are deemed “true” (1).
TABLE 6 Summary of published results of S. pyogenes in vitro susceptibility to SXTa
Publication Yr Country Method and medium used Findings Resistance
Yourassowsky et al. (54) 1974 Belgium AST determined by the agar
dilution method on Wellcotest
agar supplemented with 5%
lysed horse blood
59/59 strains of S. pyogenes
susceptible to TMP,
SMZ, and SXT
0%
Finland et al. (22) 1976 United States Plate dilution method on a
modified thymidine-deficient
Mueller-Hinton medium
containing 5% laked blood
35/35 strains of S. pyogenes
susceptible to SXT; 32/
35 strains of S. pyogenes
susceptible to SMZ
alone
0%
Darrell et al. (14) 1968 United Kingdom MIC determined by the plate
dilution method on diagnostic
sensitivity agar containing 5%
lysed horse blood
14/14 strains of S. pyogenes
susceptible to TMP with
MIC 1 g/ml
0%
Liebowitz et al. (36) 2003 South Africa MICs determined by the broth
microdilution method
according NCCLS guidelines
66/66 S. pyogenes strains
susceptible to SXT
0%
Hartman and Hoes (26) 1949 United States Wilson’s method (53, 53a), a
semi-solid medium with low
sulfonamide antagonist content
94/96 strains of S. pyogenes
susceptible to
sulfadiazine
1.9%
Schultz and Frank (44) 1958 United States Wilson’s method (53, 53a), a
semi-solid medium with low
sulfonamide antagonist content
84/86 strains of S. pyogenes
susceptible to sulfur
antibiotics
2.3%
Eliopoulos and
Wennersten (18)
1997 United States MICs determined by agar dilution
methods on Mueller-Hinton II
agar 5% lysed horse blood or
with thymidine phosphorylase
at 0.2 IU/ml added
58/60 S. pyogenes
susceptible to SXT
3.3%
Berger-Rabinowitz and
Davies (2)
1970 Israel Wilson’s method (53, 53a), a
semi-solid medium with low
sulfonamide antagonist content
849/890 S. pyogenes strains
susceptible to
sulfadiazine
4.6%
Dhanda et al. (15a) 2011 India Kirby-Bauer disk-diffusion test as
per CLSI guidelines; agar not
specified
24/26 S. pyogenes strains
susceptible to SXT
6.7%
Bushby (6) 1973 United States Disk diffusion using TMP/SMZ
disks 1.25/23.75 g on various
media
699/757 S. pyogenes strains
susceptible to SXT
7.7%
Lakshmy et al. (34a) 2011 India Kirby-Bauer disk-diffusion test as
per CLSI guidelines. Agar not
specified
95/119 S. pyogenes strains
susceptible to SXT
21.8%
Dumre et al. (16a) 2009 Nepal Kirby-Bauer disk-diffusion test as
per CLSI guidelines; agar not
specified
11/38 S. pyogenes strains
susceptible to SXT
71%
Traub and Leonhard (51) 1997 Germany Agar disk diffusion using NCCLS
criteria on sheep blood MHA
0/63 strains of S. pyogenes
susceptible to SXT
100%
Kaplan et al. (33) 1999 United States Etest performed on MHA
containing 5% sheep blood
0/169 strains of S. pyogenes
susceptible to SXT with
MIC 32 g/ml
100%
a TMP, trimethoprim, SMZ, sulfamethoxazole.
Bowen et al.
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The in vitro results reported in the current study confirming
the susceptibility of S. pyogenes to SXT suggest that treatment of
SSTIwith SXT isworth considering.Our currentRCT to assess the
noninferiority of SXT to the standard treatment with benzathine
penicillin G (BPG) for impetigo will provide the necessary clinical
evidence to inform guidelines. It is based on a pilot study of 13
participants which indicated that both BPG and SXT were effica-
cious in healing impetigo (48). There is one study published com-
paring these agents for S. pyogenes infection in tonsillitis, which
reported a 70% treatment efficacy for SXT compared to 88% for
penicillin, a non-statistically significant difference (52).
The infrequent reports of susceptibility of S. pyogenes to SXT
demonstrate resistance rates ranging from 0% to 100%depending
on which medium and testing conditions are used (Table 6). Al-
though the variation in results may relate to the particular strains
included or the local prescribing patterns of SXT, it is most likely
related to the methodology of testing. All of the studies reporting
high resistance rates either used media known to have high con-
centrations of thymidine or did not provide details of themedium
used. As standardization to ensure a low thymidine concentration
of Mueller-Hinton medium was introduced only in 2006, it is
likely that, unless low-thymidine media were specified (2, 14, 18,
22, 26, 44, 54), studies in publications prior to this may not have
controlled for thymidine content.
Alongside this, S. pyogenes has remained 100% susceptible in
vitro to penicillin. Hence there has been no pressing need to un-
derstand SXT susceptibility as an alternative antibacterial in the
public health approach to treatment of S. pyogenes infections.
However, this is changing in the context of rising MRSA rates for
SSTI.
Our results show that testing of S. pyogenes for susceptibility to
SXT on MHS gives a higher MIC than all of the other agars, al-
though the organism remains in the susceptible range. This could
possibly be due to the availability of thymidine or other inhibitory
substances in this medium. However, thymidine concentrations
of the various media utilized were not assessed. Alternatively, the
absence of an enzyme to reduce the inhibition in sheep blood
compared to horse blood may be the explanation.
The original paper describing the identification of the Harper-
Cawston factor (25) as thymidine (21) reports an interesting ob-
servation that our study has partially demonstrated. Only lysed
horse blood contains thymidine phosphorylase to convert thymi-
dine to thymine and hence overcome the inhibition of folate me-
tabolism that occurs in the presence of thymidine. No othermam-
malian blood contains this enzyme, which is a possible reason for
the higherMICs reported onMHS than on those agars containing
horse blood. In the original paper, the presence of thymidine at
concentrations of 1.6 g/ml was sufficient to completely prevent
inhibition by the drugs. The inclusion of lysed horse blood re-
stored the inhibition. This has also been shown by Coll et al. (11).
However, the MIC of S. pyogenes isolates tested onMHLHBA was
higher than those of isolates tested on MHF (study 2), MHA
(studies 1 and 2), orMHBA (study 1), which suggests other factors
at play.
A limitation of this study is the reliance upon a single method
for susceptibility testing, the Etest, which is a commercially de-
rivedmethod. Further work using broth or agar dilutionmethods
would add to our understanding of the susceptibility of S. pyogenes
to SXT. As shown in Table 6, when these additional methods have
been assessed, the susceptibility of S. pyogenes ranges from 0%
(54) to 3.3% (18) resistant, similarly low resistances to those re-
ported in this study.
Reading MICs for SXT can be challenging due to haze. In par-
ticular, only faint growth of S. pyogenes was achieved on MHA
(due to the absence of blood), and this made reading endpoints
more difficult.MHLHBA andMHFhad problems similar to those
of MHA with respect to haze. Despite this in study 2, the MICs
were reproducible between readers, with a high level of interrater
reliability within 1 MIC gradation.
Conclusions. The widespread belief that SXT is ineffective for
S. pyogenes infections because of inherent antimicrobial resistance
is a fallacy due to technical limitations in laboratorymethodology:
namely, the use of media containing high concentrations of thy-
midine, which inhibits the action of sulfur antibacterials. When
media containing low concentrations of thymidine and/or high
concentrations of the enzyme thymidine phosphorylase are used,
resistance rates are low in most cases, although this must be mon-
itored over time and may vary with local epidemiology and anti-
bacterial prescribing patterns. This study provides justification to
proceed to clinical trials of SXT for S. pyogenes infections. Corrob-
oration with clinical trial data may convince clinicians that SXT
can safely and appropriately be used for infections involving S.
pyogenes. The Skin Sore Trial will answer the clinical applicability
of this current in vitro study. In the era of risingMRSA prevalence,
more clinical trials of SXT for treatment of SSTI, where S. pyogenes
and S. aureus are frequently copathogens, are needed.
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